{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:10:26Z","timestamp":1772759426460,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"s389","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":4008,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1996,9]]},"abstract":"<jats:p>The extrapyramidal side\u2010effects (EPS) of conventional neuroleptics are widely recognized. However, a substantial number of drug\u2010na\u00efve patients exhibit movement disorders which could be mistaken for EPS if drug therapy were started without a careful baseline assessment. Patients' experience of EPS during their first exposure to antipsychotic medication can have lasting effects on their attitudes to medication and compliance. Unmedicated, approximately 60% of patients will relapse in the first year after resolution of an acute psychotic episode, whereas prophylactic medication can reduce the relapse rate to less than 20%. The conventional neuroleptics produce antipsychotic effects at doses which differ little from those that induce EPS, and although anticholinergic medication helps to reduce the severity of EPS, it also causes side\u2010effects, e.g. constipation, blurred vision, retention of urine, dry mouth and disturbances of sexual function. More importantly, anticholinergic drugs may worsen the psychosis and impair memory. Low or intermittent dose strategies with conventional neuroleptics may give patients relief from EPS, but they increase the relapse risk, and may also increase the risk of tardive dyskinesia. The serotonin\u2010dopamine antagonist (SDA) antipsychotics, such as risperidone, produce both significant antipsychotic effects at doses which are lower than those that cause EPS, and also a lower level of EPS compared with conventional drugs. Clinical trials have shown that risperidone is effective in first\u2010episode schizophrenia. In these trials the same doses were used as in chronic patients. However, clinical experience in Canada since the drug became generally available in 1993 suggests that first\u2010episode patients require lower doses of risperidone than chronically ill patients who have had several acute psychotic episodes. More than 3 years of use has made it clear that risperidone should be seriously considered in first\u2010episode patients, as it offers an opportunity to treat psychosis with minimal EPS. This in turn should lead to better compliance and a lower long\u2010term relapse rate.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1996.tb05943.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T13:49:08Z","timestamp":1187876948000},"page":"12-17","source":"Crossref","is-referenced-by-count":27,"title":["Spontaneous and drug\u2010induced movement disorders in schizophrenia"],"prefix":"10.1111","volume":"94","author":[{"given":"L. C.","family":"Kopala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.12.1724"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.9.1343"},{"issue":"4","key":"e_1_2_1_4_2","first-page":"52","article-title":"Tardive dyskinesia: prevalence, incidence and risk factors","volume":"8","author":"Kane JM","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_1_5_2","first-page":"1825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder SR","year":"1994","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199302000-00004"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.6.712"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.2.191"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1017\/S003329170000622X"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199502001-00003"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(96)00008-9"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.12.1819"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810320063009"},{"issue":"1","key":"e_1_2_1_14_2","first-page":"2","article-title":"The natural course of schizophrenia and effective maintenance therapy","volume":"6","author":"Davis JM","year":"1986","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760130049008"},{"key":"e_1_2_1_16_2","first-page":"425","article-title":"Extrapyramidal modifications of fine movements\u2014a \u2018conditio sine qua non\u2019 of fundamental therapeutic action of neuroleptic drugs","volume":"20","author":"Haase HJ","year":"1961","journal-title":"Rev Canada Biol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700047942"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.139.11.1460"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000200664"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.143.6.584"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1980.tb00875.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6756.837"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810280049007"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/17.2.263"},{"issue":"5","key":"e_1_2_1_25_2","first-page":"5","article-title":"Risperidone: a novel antipsychotic with balanced serotonindopamine antagonism, receptor occupancy profile and pharmacologic activity","volume":"55","author":"Leysen JH","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_1_26_2","volume-title":"The action of neuroleptic drugs","author":"Haase HJ","year":"1965"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.3928\/0048-5713-19950501-09"},{"key":"e_1_2_1_28_2","unstructured":"EmsleyRA McCreadieR LivingstonM deSmedtG LemmensP.Risperidone in the treatment of first\u2010episode patients with schizophreniform disorder: a double\u2010blind multicentre study. Poster presentation at Campaign on Schizophrenia Conference \u2018Critical Issues in Treatment\u2019 Florence March1995."},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00500-5"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.162.1.80"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014288"},{"key":"e_1_2_1_32_2","first-page":"499","volume-title":"Clinical neuropsychology","author":"Randolph C","year":"1993"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.9.1183"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1996.tb05943.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1996.tb05943.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:57:46Z","timestamp":1695743866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1996.tb05943.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,9]]},"references-count":32,"journal-issue":{"issue":"s389","published-print":{"date-parts":[[1996,9]]}},"alternative-id":["10.1111\/j.1600-0447.1996.tb05943.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1996.tb05943.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,9]]}}}